Abstract
Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development1,2,3,4,5. This also applies to the PI3K signalling pathway, which has been extensively targeted by inhibitors for conditions with PI3K overactivation, such as cancer and immune dysregulation. Here we report the discovery of UCL-TRO-1938 (referred to as 1938 hereon), a small-molecule activator of the PI3Kα isoform, a crucial effector of growth factor signalling. 1938 allosterically activates PI3Kα through a distinct mechanism by enhancing multiple steps of the PI3Kα catalytic cycle and causes both local and global conformational changes in the PI3Kα structure. This compound is selective for PI3Kα over other PI3K isoforms and multiple protein and lipid kinases. It transiently activates PI3K signalling in all rodent and human cells tested, resulting in cellular responses such as proliferation and neurite outgrowth. In rodent models, acute treatment with 1938 provides cardioprotection from ischaemia–reperfusion injury and, after local administration, enhances nerve regeneration following nerve crush. This study identifies a chemical tool to directly probe the PI3Kα signalling pathway and a new approach to modulate PI3K activity, widening the therapeutic potential of targeting these enzymes through short-term activation for tissue protection and regeneration. Our findings illustrate the potential of activating kinases for therapeutic benefit, a currently largely untapped area of drug development.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
All raw images for the TIRF microscopy experiments are provided at the Open Science Framework (https://osf.io/gzxfm/). MS data (raw and processed data) have been deposited into the ProteomeXchange Consortium through the PRIDE partner repository77 with the dataset identifier PXD037721. The MS proteomics data have been deposited into the ProteomeXchange Consortium through the PRIDE partner repository with the dataset identifier PXD027993. Crystallography data have been deposited into the PDB91 (https://www.rcsb.org/) with the following identifiers: 8BFU (apo p110α)[8OW2 (p110α/1938 complex); 7PG5 (apo p110α/p85α); and 7PG6 (BYL719–p110α/p85α). Protein structures used for analysis are available from the PDB database (4JPS, 4ZOP and 4OVV). Protein sequences (PIK3CA, PIK3CB and PIK3CD) were obtained from the UniProt database (https://www.uniprot.org/). The other data that support the findings in this study are available from the corresponding author upon request. Source data are provided with this paper.
Code availability
All macros and R analysis scripts for the TIRF microscopy experiments are provided at the Open Science Framework (https://osf.io/gzxfm/). MS scripts have been deposited into the ProteomeXchange Consortium through the PRIDE partner repository77 with the dataset identifier PXD037721.
References
Cowan-Jacob, S. W., Jahnke, W. & Knapp, S. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med. Chem. 6, 541–561 (2014).
Astl, L., Tse, A. & Verkhivker, G. M. Interrogating regulatory mechanisms in signaling proteins by allosteric inhibitors and activators: a dynamic view through the lens of residue interaction networks. Adv. Exp. Med. Biol. 1163, 187–223 (2019).
Simpson, G. L., Hughes, J. A., Washio, Y. & Bertrand, S. M. Direct small-molecule kinase activation: novel approaches for a new era of drug discovery. Curr. Opin. Drug Discov. Dev. 12, 585–596 (2009).
Fang, Z., Grutter, C. & Rauh, D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem. Biol. 8, 58–70 (2013).
Mobitz, H., Jahnke, W. & Cowan-Jacob, S. W. Expanding the opportunities for modulating kinase targets with allosteric approaches. Curr. Top. Med. Chem. 17, 59–70 (2017).
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., Andre, F. & Okkenhaug, K. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 20, 741–769 (2021).
Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605–635 (2017).
Borges, G. A. et al. Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration. Regen. Med. 15, 1329–1344 (2020).
Matsuda, S. et al. Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (review). Int. J. Oncol. 49, 1785–1790 (2016).
Koh, S. H. & Lo, E. H. The role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction. J. Clin. Neurol. 11, 297–304 (2015).
Hausenloy, D. J. & Yellon, D. M. New directions for protecting the heart against ischaemia–reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc. Res. 61, 448–460 (2004).
Catanese, L., Tarsia, J. & Fisher, M. Acute ischemic stroke therapy overview. Circ. Res. 120, 541–558 (2017).
Bala, F. et al. Infarct growth despite successful endovascular reperfusion in acute ischemic stroke: a meta-analysis. Am. J. Neuroradiol. https://doi.org/10.3174/ajnr.A7177 (2021).
Heusch, G. Myocardial ischaemia–reperfusion injury and cardioprotection in perspective. Nat. Rev. Cardiol. 17, 773–789 (2020).
Chauhan, A. et al. PTEN inhibitor bpV(HOpic) confers protection against ionizing radiation. Sci. Rep. 11, 1720 (2021).
Iosifidis, T. et al. Aberrant cell migration contributes to defective airway epithelial repair in childhood wheeze. JCI Insight https://doi.org/10.1172/jci.insight.133125 (2020).
Arnes, M., Romero, N., Casas-Tinto, S., Acebes, A. & Ferrus, A. PI3K activation prevents Aβ42-induced synapse loss and favors insoluble amyloid deposit formation. Mol. Biol. Cell 31, 244–260 (2020).
Cuesto, G. et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J. Neurosci. 31, 2721–2733 (2011).
Asua, D., Bougamra, G., Calleja-Felipe, M., Morales, M. & Knafo, S. Peptides acting as cognitive enhancers. Neuroscience 370, 81–87 (2018).
Nieuwenhuis, B. et al. PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS. EMBO Mol. Med. 12, e11674 (2020).
Prakoso, D. et al. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes. Am. J. Physiol. Heart. Circ. Physiol. 318, H840–H852 (2020).
Chen, S. et al. Neuroprotective role of the PI3 kinase/Akt signaling pathway in zebrafish. Front. Endocrinol. 8, 21 (2017).
Ohtake, Y., Hayat, U. & Li, S. PTEN inhibition and axon regeneration and neural repair. Neural Regen. Res. 10, 1363–1368 (2015).
Derossi, D., Williams, E. J., Green, P. J., Dunican, D. J. & Doherty, P. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide. Biochem. Biophys. Res. Commun. 251, 148–152 (1998).
Jo, H. et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc. Natl Acad. Sci. USA 109, 10581–10586 (2012).
Zheng, K. et al. Activation of Akt by SC79 protects myocardiocytes from oxygen and glucose deprivation (OGD)/re-oxygenation. Oncotarget 8, 14978–14987 (2017).
Spinelli, L., Lindsay, Y. E. & Leslie, N. R. PTEN inhibitors: an evaluation of current compounds. Adv. Biol. Regul. 57, 102–111 (2015).
Furet, P. et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg. Med. Chem. Lett. 23, 3741–3748 (2013).
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O. & Williams, R. L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl Acad. Sci. USA 109, 15259–15264 (2012).
Huang, C. H. et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318, 1744–1748 (2007).
Chen, P. et al. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design. Protein Sci. 23, 1332–1340 (2014).
MarvinSketch, pKa plug-in v.21.14 (Chemaxon).
Maheshwari, S. et al. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. J. Biol. Chem. 292, 13541–13550 (2017).
Pirola, L. et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase α (PI3Kα). Functions of lipid kinase-deficient PI3Kα in signaling. J. Biol. Chem. 276, 21544–21554 (2001).
Yang, H. et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552, 368–373 (2017).
Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941–D947 (2019).
Clark, J. et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat. Methods 8, 267–272 (2011).
Foukas, L. C. et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006).
Knight, Z. A. et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733–747 (2006).
Tsolakos, N. et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc. Natl Acad. Sci. USA 115, 12176–12181 (2018).
Malek, M. et al. PTEN regulates PI(3,4)P2 signaling downstream of class I PI3K. Mol. Cell 68, 566–580.e10 (2017).
Gerber, D. E. et al. Stromal platelet-derived growth factor receptor alpha (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts. Mol. Cancer Ther. 11, 2473–2482 (2012).
Goulden, B. D. et al. A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product. J. Cell Biol. 218, 1066–1079 (2019).
Liu, Y. & Bankaitis, V. A. Phosphoinositide phosphatases in cell biology and disease. Prog. Lipid Res. 49, 201–217 (2010).
Majerus, P. W. & York, J. D. Phosphoinositide phosphatases and disease. J. Lipid Res. https://doi.org/10.1194/jlr.R800072-JLR200 (2009).
Ramos, A. R., Ghosh, S. & Erneux, C. The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease. J. Lipid Res. 60, 276–286 (2019).
Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107, 11381–11386 (2010).
Rozengurt, E., Soares, H. P. & Sinnet-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol. Cancer Ther. 13, 2477–2488 (2014).
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512–D520 (2015).
Hausenloy, D. J. & Yellon, D. M. Myocardial ischemia–reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 123, 92–100 (2013).
Hausenloy, D. J. & Yellon, D. M. Preconditioning and postconditioning: united at reperfusion. Pharmacol. Ther. 116, 173–191 (2007).
Jonassen, A. K. et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J. Mol. Cell. Cardiol. 32, 757–764 (2000).
Rossello, X. et al. The role of PI3Kα isoform in cardioprotection. Basic Res. Cardiol. 112, 66 (2017).
Madsen, R. R. & Vanhaesebroeck, B. Cracking the context-specific PI3K signaling code. Sci. Signal. https://doi.org/10.1126/scisignal.aay2940 (2020).
Kinross, K. M. et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553–557 (2012).
Berenjeno, I. M. et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nat. Commun. 8, 1773 (2017).
Madsen, R. R., Vanhaesebroeck, B. & Semple, R. K. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol. Med. 24, 856–870 (2018).
Lu, Y. et al. Rationally designed PI3Kα mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors. J. Mol. Biol. 429, 1684–1704 (2017).
Anandapadamanaban, M. et al. Architecture of human Rag GTPase heterodimers and their complex with mTORC1. Science 366, 203–210 (2019).
Masson, G. R. et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat. Methods 16, 595–602 (2019).
Eid, S., Turk, S., Volkamer, A., Rippmann, F. & Fulle, S. KinMap: a web-based tool for interactive navigation through human kinome data. BMC Bioinformatics 18, 16 (2017).
Baretic, D. et al. Structures of closed and open conformations of dimeric human ATM. Sci. Adv. 3, e1700933 (2017).
Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. Science 330, 517–521 (2010).
Stock, D., Perisic, O. & Lowe, J. Robotic nanolitre protein crystallisation at the MRC Laboratory of Molecular Biology. Prog. Biophys. Mol. Biol. 88, 311–327 (2005).
Cianci, M. et al. P13, the EMBL macromolecular crystallography beamline at the low-emittance PETRA III ring for high- and low-energy phasing with variable beam focusing. J. Synchrotron Radiat. 24, 323–332 (2017).
Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013).
Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22–25 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Winter, G., Lobley, C. M. & Prince, S. M. Decision making in xia2. Acta Crystallogr. D Biol. Crystallogr. 69, 1260–1273 (2013).
Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).
Conant, D. et al. Inference of CRISPR edits from Sanger trace data. CRISPR J. 5, 123–130 (2022).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
Choi, M. et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 30, 2524–2526 (2014).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
Anderson, K. E., Juvin, V., Clark, J., Stephens, L. R. & Hawkins, P. T. Investigating the effect of arachidonate supplementation on the phosphoinositide content of MCF10a breast epithelial cells. Adv. Biol. Regul. 62, 18–24 (2016).
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
Feoktistova, M., Geserick, P. & Leverkus, M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb. Protoc. 2016, pdb.prot087379 (2016).
Botker, H. E. et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res. Cardiol. 113, 39 (2018).
Melli, G. & Hoke, A. Dorsal root ganglia sensory neuronal cultures: a tool for drug discovery for peripheral neuropathies. Expert Opin. Drug Discov. 4, 1035–1045 (2009).
Rayner, M. L. D. et al. Developing an in vitro model to screen drugs for nerve regeneration. Anat. Rec. 301, 1628–1637 (2018).
Wood, M. D., Kemp, S. W., Weber, C., Borschel, G. H. & Gordon, T. Outcome measures of peripheral nerve regeneration. Ann. Anat. 193, 321–333 (2011).
Caillaud, M., Richard, L., Vallat, J. M., Desmouliere, A. & Billet, F. Peripheral nerve regeneration and intraneural revascularization. Neural Regen. Res. 14, 24–33 (2019).
Alvites, R. et al. Peripheral nerve injury and axonotmesis: state of the art and recent advances. Cogent Med. 5, 1466404 (2018).
Lancashire, H. T. et al. Microchannel neural interface manufacture by stacking silicone and metal foil laminae. J. Neural Eng. 13, 034001 (2016).
Shefner, J. M., Cudkowicz, M. & Brown, R. H. Jr. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve 34, 603–607 (2006).
Jacobsen, A. B., Bostock, H. & Tankisi, H. CMAP Scan MUNE (MScan)—a novel motor unit number estimation (MUNE) method. J. Vis. Exp. https://doi.org/10.3791/56805 (2018).
Arnold, W. D. et al. Electrophysiological motor unit number estimation (MUNE) measuring compound muscle action potential (CMAP) in mouse hindlimb muscles. J. Vis. Exp. https://doi.org/10.3791/52899 (2015).
Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235–242 (2000).
Acknowledgements
We thank D. Petrovic, A. Davis, G. Pairaudeau, S. Cosulich and R. Knoll (AstraZeneca) for advice and support; C. Boshoff, D. Linch, B. Williams, D. Miller, N. McNally and A. Holmes (UCL/UCLH) for support during the early stages of this work; O. Perisic for help with cloning and protein expression (MRC-LMB); S. Arjun and P. Golforoush (The Hatter Cardiovascular Institute) for help with the analysis of the cardioprotection experiments; Y. Posor (UCL) and G. Hammond (University of Pittsburgh) for help and advice with TIRF microscopy; F. Gorrec (MRC-LMB) for advice on crystallization; N. Vasan (Columbia University) for the gift of the Flag–PIK3R1 plasmid; J. Shi (MRC-LMB) for help with insect cell culture; M. Schimpl (AstraZeneca) for help with Mogul geometry analysis; M. Graupera (Barcelona), E. Aksoy (London), L. Foukas (London) and K. Okkenhaug (Cambridge) for extensive feedback on manuscript; J. Kinghorn and the other team members of the UCL Translational Research Office, A. Sullivan and V. Dominguez for general support; D. Leisi, R. Colman and S. Garcia Gomez (UCLB) for business support; staff at the Diamond Light Source (DLS-UK) and EMBL-Hamburg (PETRA III/DESY, Germany) for beamtime (proposals mx23583 and mx28677 – DLS; and mx647- EMBL); the staff of beamlines i03 (DLS), i04 (DLS), i24 (DLS) and P13 (EMBL-Hamburg) for assistance with crystal testing and data collection; and staff at the Diamond-CCP4 Data Collection and Structure Solution Workshop 2022 for training. This research was funded in part by the Wellcome Trust and UKRI (BBRSRC and MRC). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Grant funding details are as follows: UK NIHR UCLH Biomedical Research Centre (to B.V. (High Impact Experimental Medicine Initiative BRC80a/HI/TE/5995 and BRC80b/HI/TE/5995), to B.V. and R.A. (BRC504/CV/BV/101320, BRC732/JK/101400 and RCF309/BVH/101440/2017) and to the UCL Drug Discovery Group (BRC247/HI/DM/101440 and BRC454/HI/JK/104360)); MRC (to R.L.W. (MC_U105184308); to B.V. and R.A. (UCL Proximity to Discovery Fund (MC_PC_15063, MC_PC_16087 and MC_PC_17202); MRC Confidence in Concept (MC_PC_16063 and MC_PC_18063); to G.R.M. and V.V. (MRC iCase Studentship (MR/R01579/1)); to G.R.M. and R.L.W. (Blue Sky collaboration MRC Laboratory of Molecular Biology and AstraZeneca (BSF33)); the Rosetrees Trust (to V.R. (Rosetrees Trust Seedcorn 2020 (100049)) and J.B.P. (UCL Rosetrees Stoneygate Prize 2018; M827)); Cancer Research UK (to B.V. (C23338/A29269 and C23338/A25722)); the BBSRC (to R.A. and B.V. (BBSRC Global Challenges Research Fund Impact Acceleration Account GCRF-IAA), to G.R.M. (BBSRC Capital Equipment Grant BB/V019635/1), and to L.R.S., P.T.H. and K.E.A. (BBSRC Institute Strategic Programme Grant BB/PO13384/1)); the British Heart Foundation (to S.M.D., D.M.Y., B.V. and R.A. (PG/18/44/33790)); the Fidelity Foundation (to T.D.B. and M.K. (180348)) and the UCL Enterprise HEIF Knowledge Exchange and Innovation Fund (to R.A. (KEI2017-05-18)). The UCL Drug Discovery Group received additional support from the Wellcome Trust (Institutional Strategic Support Fund; awarded to UCL (105604/Z/14/Z and 204841/Z/16/Z), with subaward to the Drug Discovery Group (ISSF2/H17RCO/033 and ISSF3/H17RCO/006)). A.B. is supported by a CRUK Cancer Immunotherapy Network Accelerator (CITA) Award (C33499/A20265) and a CRUK UCL Centre award (C416/A25145). S.S. and the UCL Cancer Institute Translational Technology Platforms are supported by a CRUK UCL Centre Award (C416/A25145). Personal fellowships were from EU Marie Skłodowska-Curie (to G.Q.G. (contract number 839032) and S.E.C. (contract number 838559)) and the Wellcome Trust (to R.R.M. (220464/Z/20/Z)). G.R.M. was supported by the AstraZeneca/LMB Blue Sky Initiative (MC-A024-5PF9G to R.L.W.) and a Henslow Research Fellowship from The Cambridge Philosophical Society and St Catharine’s College, Cambridge, UK.
Author information
Authors and Affiliations
Contributions
B.V. provided the initial study conceptualization, with input from R.A., R.L.W., D.M.S., S.M.D. and D.M.Y. B.V. took the lead in writing the manuscript, with major input from G.Q.G., B.B., B.A., V.R., T.A., R.R.M., S.E.C., S.M.D., J.B.P. and R.L.W., with other authors contributing to manuscript editing and finalization. G.Q.G., B.B., B.A., G.R.M., V.R., T.A., S.O., R.R.M., S.E.C., D.B., O.N., Z.H., B.W., S.H.M., A.W.E.C., V.V., K.E.A., N.P., E.L.-G. and J.B.P. designed and performed experiments and data analyses supporting the study. M.F., M.C., I.F. and A.M. supported the HCS and drug modelling studies. D.M., A.B., S.S., M.W., A.H., C.P. and T.D.B. performed experiments and analysis. M.A.W. and M.K. provided general support. B.V., R.A., J.B.P. and R.L.W. supervised the study, with input from D.M.S., D.M.Y., S.M.D., L.R.S. and P.T.H. D.M.Y., S.M.D., D.M.S., J.B.P., R.A. and R.L.W. are joint senior authors.
Corresponding author
Ethics declarations
Competing interests
B.V. is a consultant for iOnctura, Venthera, Pharming and Olema Pharmaceuticals, and has received speaker fees from Gilead. M.F., M.C., I.F., A.M. and D.M.S. are or were employees and shareholders in AstraZeneca at the time of the work done. J.B.P. is co-Founder and Chief Scientific Officer of the UCL spin-out company Glialign. A patent application WO2023041905, with relevance to this work has been filed by UCL Business Ltd, covering ‘Aminopyridines as activators of PI 3 kinase’ that lists B.A., T.A, S.O., E.A.W.C., H.E., D.M.Y., R.A, R.L.W. and B.V. as inventors. The other authors declare no competing interests.
Peer review
Peer review information
Nature thanks John Burke, Arvin (C.) Dar and Takehiko Sasaki for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Additional biochemical data on 1938.
a, Determination of Kd for the dissociation of 1938 from p110α/p85α by surface plasmon resonance (SPR). SPR equilibrium response titration of 1938 binding to immobilized p110α/p85α, yielding a dissociation constant Kd = 36 ± 5 µM. b, Determination of Kd for the dissociation of 1938 from p110α/p85α by differential scanning fluorimetry (DSF). The first derivatives of the fluorescence change of p110α/p85α upon thermal denaturation at the stated 1938 concentrations (left panel) were used to plot the melting temperature (Tm) (right panel). Fits to data gave a Kd = 16 ± 2 µM. Kd shown as mean ± SD (n = 3 independent experiments). Representative experiment is shown. c, Effect of 1938 on the IC50 of BYL719 for PI3Kα. Data shown as mean ± SEM (n = 3 independent experiments). d, Activation of class IA PI3K isoforms by a concentration range of pY using the ADP-Glo assay. Data shown as mean ± SEM (n = 3 independent experiments).
Extended Data Fig. 2 Additional data on HDX-MS and crystallography.
Structural changes induced by BYL719 (a), or 1938 in combination with BYL719 (b), assessed by HDX-MS in full-length p110α/p85α, highlighted on the structure of p110α (gray)/niSH2-p85α (green) (PDB: 4ZOP). Selection threshhold for significant peptides: a-b difference ≥2.5%, Da difference ≥0.25, p-value <0.05 (unpaired t-test). c, Peptide uptake from HDX-MS. A selection of peptides (peptides 848-859, 532-551, 1002-1013 and 1006-1016 are from p110α, peptide 555-570 is from p85α) exhibiting significant differences in solvent exchange rates on the addition of 1938 (red), BYL719 (green), both (purple) or neither (blue). Data presented here is from one of three biological replicates Five time points were measured in triplicate. Each point is the mean of one biological repeat. d, Omit map of ligand 1938 (mFo-DFc) calculated at +/− 3 σ using phenix.polder. e, 1938 bound to p110α shown in multiple orientations. f, Two possible orientations shown for the 1938 ligand (magenta and yellow sticks) in the p110α crystal structure, both fit the Sigma-weighted density map (blue; 2mFo-DFc) equally well. Yellow dashes show predicted hydrogen bonds.g, Effect of 1938 on catalytic activity of p110α proteins with mutations in the 1938-binding pocket. Data shown as mean ± SEM (n = 4 independent experiments).
Extended Data Fig. 3 Additional data on 1938-driven signalling.
a, MEFs were stimulated at different time points with 1938 (5 µM) or for 2 min with PDGF (20 ng/ml), followed by lipid extraction and PtdIns(3,4)P2 measurement by mass spectrometry. b, MEFs were stimulated for 2 min with 1938 (30 µM) or PDGF (0.5 or 1 ng/ml), followed by lipid extraction and PtdIns(3,4)P2 measurement by mass spectrometry. (a,b) n = independent experiments, shown in figure. Error bars represent SD. c, Control TIRF microscopy data from DMSO-treated HeLa cells expressing the PtdIns(3,4,5)P3 or the PtdIns(3,4)P2 reporter. HeLa cells expressing the EGFP-tagged PIP3 reporter PH-ARNO-I303Ex2 (ARNO) (black lines) or the PtdIns(3,4)P2 reporter mCherry-cPH-TAPP1x3 (blue lines) were stimulated with DMSO as indicated. Overlay plots (mean ± SEM) were generated by scaling to minimum and maximum values of the normalised fluorescence intensity for each time point (Fn(t)). PtdIns(3,4,5)3 reporter data are representative of 2 experiments and 16 single cells. PtdIns(3,4)P2 reporter data are representative of 4 experiments and 28 single cells. Individual measurements were acquired every 2 min. d, pAKTS473 induction by 1938 in PI3Kα-KO MEFs transiently transfected with p110α-WT or p110α-mutants. Blot representative of n = 2 experiments. e, Time course analysis of 1938-induced pAKTS473 in A549 by 1938+BYL719 or a saturating insulin concentration. Blot representative of n = 3 experiments. f, Time course analysis of 1938-induced pAKTS473 and pS6S240/244 in MCF10A cells in the presence or absence of BYL719. Shown is a representative blot of n = 2 independent experiments. g, Time course analysis of insulin- or 1938-induced PI3K/AKT/mTORC1 signalling in A549, n = 2 experiments.
Extended Data Fig. 4 In vitro selectivity profile of 1938 (1 µM) on 133 protein kinases and 7 lipid kinases. visualised as a waterfall plot.
In the waterfall plot, the protein and lipid kinases are labelled in black and red, respectively, with the dashed line delineating 25% of kinase inhibition.
Extended Data Fig. 5 In vitro selectivity profile of 1938 (1 µM) on 133 protein kinases and 7 lipid kinases.
visualised as a kinome tree using KinMap.
Extended Data Fig. 6 Effect of 1938 on in vitro kinase activity of the PI3K-related kinases ATM and mTORC1 (mTOR/RAPTOR/LST8 complex).
The kinases were incubated at 30 °C for 30 min (ATM) or 3 h (mTORC1), with or without 200 µM 1938 in the presence of their respective substrates (GST-p53 for ATM and 4E-BP1 for mTORC1), followed by analysis and quantification as described in Methods. The positive control for ATM was inclusion of the MRN complex (Mre11-Rad50-Nbs1), known to activate ATM, in the kinase reaction. The positive control for mTORC1 was the use of a triple amount of mTORC1 complex in the kinase reaction. Data show individual experiments (n = 3), error bars represent mean ± SD.
Extended Data Fig. 7 Phosphoproteomics experimental set-up and control data.
a, Experimental design and workflow of phosphoproteomics experiment. PI3Kα-WT and PI3Kα-KO MEFs were serum-starved overnight, stimulated with DMSO, 1938 (5 µM) or insulin (100 nM) for 15 min or 4 h and processed for phosphoproteomics analysis. 10,611 phosphosites fom 3,093 proteins were analysed by MSstats, the majority of which were pSer and pThr residues. b, Validation of phosphoproteomics conditions. PI3Kα-WT and PI3Kα-KO MEFs were serum-starved overnight and stimulated with DMSO, 1938 (5 µM) or insulin (100 nM) for 15 min or 4 h as indicated. Lysates were immunoblotted with antibodies to pAKTS473, pAKTT308, total AKT, pPRAS40/AKT1S1T247, pS6RPS240/244, S6RP or GAPDH. Samples were from a representative phosphoproteomics experiment. Representative of n = 2 independent experiments. c, Volcano plot of phosphosites differentially regulated by 1938 (5 µM) relative to DMSO in PI3Kα-WT MEFs. Note, these data are reproduced, enlarged and labelled from Fig. 4b. Red, upregulated phosphosites, Green, downregulated phospho-sites. Boxed phosphosites have been previously reported to be regulated by PI3K signalling (PhosphoSitePlus). d, Insulin stimulation induces phosphorylation of expected PI3K targets in PI3Kα-WT MEFs. Volcano plot of Log2(fold change) versus -log10(adjusted p-value) for phosphosites differentially regulated by (right) 15 min or (left) 4 h 100 nM insulin treatment in PI3Kα-WT MEFs relative to DMSO-treated cells. e, High experimental reproducibility of phosphoproteomics experiment. Quantified phosphopeptides were analysed within the model-based statistical framework MSstats. Data were log2 transformed, quantile normalised, and a linear mixed-effects model was fitted to the data. The group comparison function was employed to test for differential abundance between conditions. p-values were adjusted to control the FDR using the Benjamini-Hochberg procedure. Multi-scatter plot of the Log2(intensity) of signals obtained from each replicate against the Log2(intensity) of the same sample from all other replicates. Numbers indicate the Pearson correlation coefficient for each pair.
Extended Data Fig. 8 Additional data related to the functional activities of 1938 in cultured cells, tissues and organisms.
a, Time-dependent dose-response of MEFs to 1938 as measured by CellTiter-Glo®. PI3Kα-WT and PI3Kα-KO MEFs were serum starved for 4 h, followed by stimulation with a dose range of 1938 in serum-free media for the indicated time points. Cellular metabolic activity was assessed by measurement of cellular ATP content by CellTiter-Glo®. Luminescence normalised to DMSO-only as 100%. Data shown from 2 individual experiments. b, MEFs were serum-starved overnight, followed by 24 h stimulation in serum-free medium with 1938+BYL719, insulin, or culture medium containing 10% FBS, followed by measurement of cell number (crystal violet staining). Data show 2 independent experiments. c, Ex vivo perfused Langendorff rat heart model. Generation of pAKTS473 in ischaemic hearts treated with vehicle, 1938 or insulin upon reperfusion. Rat hearts were perfused for 10 min for stabilization, followed by 45 min global ischaemia and then reperfused for 2 h. During the first 15 min of reperfusion, the buffer contained either vehicle (0.1% DMSO), 1938 (5 µM) or insulin (1 µM). After 2 h, all hearts were freeze-clamped and frozen in liquid nitrogen followed by tissue extraction in RIPA buffer, SDS-PAGE and immunoblotting with the indicated antibodies. The quantification for this blot is shown in Fig. 5d. Statistics: 1-way ANOVA with Tukey’s post test. Each lane contains the extract of an individual heart: vehicle (n = 5), 1938 (n = 6) or insulin (n = 2). d, In vivo perfused mouse heart model. Left panel, area at risk in vehicle- and 1938-treated hearts. Mice were subjected to 40 min coronary artery ligation followed by 2 h reperfusion. 15 min prior to reperfusion, 50 µl of DMSO or 10 mg/kg 1938 in DMSO, was administered i.v. Following reperfusion, the hearts were then excised, perfused with Evans Blue, sliced and stained with tetrazolium chloride, prior to blinded assessment of infarct size as a percentage of the total ischaemic “area at risk” (AAR) (this is shown in Fig. 5e). The AAR in each heart is indicated as a % of the total area of the left ventricular (LV) myocardium. Since there was no significant difference in AAR between the two groups (P = 0.86), this control measurement demonstrates experimental consistency in suture positioning etc. Statistics: Student’s unpaired 2-sided t-test, data shown as mean±SEM. Right panel, generation of pAKTS473 in ischaemic hearts treated with vehicle or 1938 upon reperfusion. 50 µl of DMSO vehicle or 10 mg/kg 1938 in DMSO was injected i.v. into anaesthetized and intubated mice. After 15 min, the chest was opened, the heart removed and immediately freeze-clamped in liquid nitrogen followed by tissue extraction in RIPA buffer, SDS-PAGE and immunoblotting with the indicated antibodies. Each lane contains the extract of an individual heart of mice treated with vehicle (n = 4) or 1938 (n = 4). The quantification for this blot is shown in Fig. 5e, right panel.
Extended Data Fig. 9 Additional and control studies for neuro-regeneration experiments.
a, Top panel; Control experiment to test the biological activity of 1938 post-freezing. An aliquot of 100 μM 1938 stock solution in dH2O and vehicle was defrosted and tested for induction of pAKTS473 by 15 min treatment of A549 cells, using insulin (1 μM) or 1938 (10 µM from control stocks in DMSO) as positive controls. Bottom panel; pAKTS473 induction in exposed sciatic nerves, injected with vehicle (autoclaved H2O) or 1938 (from stocks in autoclaved H2O) or bathed in a solution of vehicle or 1938. After 30 min, the nerves were washed and processed for analysis as described in Materials and Methods. Cell extracts of MCF7 breast cancer cells stimulated for 15 min with 5 µM 1938 or vehicle (DMSO) were loaded on the gels as positive controls. n = 1 experiment. b, Representative immunohistochemistry images of a transverse section through the distal common peroneal rat nerve, showing ChAT- and neurofilament-positive axons with tissue architecture typical of normal tissue. Scale bar = 50 µm. c, Representative immunohistochemistry images of rat TA muscle, showing a α-BTX-stained post-synaptic neuromuscular structure with associated neurofilament-positive neurons. Scale bar = 20 µm. n = 5 animals.
Extended Data Fig. 10 Additional data for methodology.
Left panel, Sanger sequencing of the genomic PIK3CA locus of A549 cell clones subjected to CRISPR/Cas9 gene-targeting. Lower traces: reference genomic PIK3CA sequence (wild-type), with the crispr RNA sequence underlined. Top traces: DNA sequence of CRISPR/Cas9 gene-targeted or control-edited A549 clones. The PIK3CA-KO clone 12 shows a +1 bp insertion (arrow), leading to frameshift and the generation of 2 consecutive premature stop-codons (asterisk) immediately downstream of the +1 bp insertion. Note that the first stop-codon occurs 80 bp upstream from the 3′ exon-exon junction and will therefore result in nonsense-mediated decay of the mRNA. The PIK3CA-WT clone 9 shows wild-type genomic DNA sequence. Right panel, Western blot for p110α using antibody CST#4255.
Supplementary information
Supplementary Information
Supplementary Tables 2a,b and 3, Supplementary Figs. 1 and 2, and legends for Supplementary Figs. 1 and 2 and for Supplementary Videos 1–4.
Supplementary Table 1
HDX data and analysis.
Supplementary Table 4
1938 Thermo Fisher SSBK-Adapta screen.
Supplementary Table 5
1938 Thermo Fisher SSBK-LanthaScreen binding.
Supplementary Table 6
1938 Thermo Fisher SSBK-Z′-LYTE screen.
Supplementary Table 7
MEF phosphoproteomics analysis of 1938 and insulin signalling.
Supplementary Table 8
MEF phosphoproteomics sites represented in PhosphoSite.
Supplementary Table 9
Geometry of 1938 checked against crystallographic database (CSD) using MOGUL.
Supplementary Video 1
Mechanisms of activation by 1938. See Supplementary Information file for the full legend.
Supplementary Video 2
Representative TIRF microscopy time-lapse videos of WT A549 cells treated with vehicle. See Supplementary Information file for the full legend.
Supplementary Video 3
Representative TIRF microscopy time-lapse videos of WT A549 cells treated with 1938. See Supplementary Information file for the full legend.
Supplementary Video 4
Representative TIRF microscopy time-lapse videos of KO A549 cells treated with 1938. See Supplementary Information file for the full legend.
Source data
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gong, G.Q., Bilanges, B., Allsop, B. et al. A small-molecule PI3Kα activator for cardioprotection and neuroregeneration. Nature 618, 159–168 (2023). https://doi.org/10.1038/s41586-023-05972-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-023-05972-2
This article is cited by
-
PI3K activator taps route to regeneration
Nature Reviews Drug Discovery (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
